FDA grants Breakthrough Therapy designation to luvesilocin for postpartum depression following positive results from the phase 2 RECONNECT trial.
4d
U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data ---- Aligned with U.S. Food and Drug Administration on ...
Researchers propose "exercise mimetics" (exercise pills) to treat depression by hacking the muscle-brain axis for those unable to physically exercise.
An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...
People with depression tend to prefer carbohydrate-rich foods, according to a new study published in Psychological Medicine. The findings point toward the possibility of dietary therapies for ...
Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
The presentation by Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma, will highlight the scientific foundation for lead candidate FMP374, the distinctive approach to modulating NMDAR, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results